

June 13, 2022

Pablo J. Cagnoni, M.D.
Chief Executive Officer
Rubius Therapeutics, Inc.
399 Binney Street, Suite 300
Cambridge, MA 02139

Therapeutics, Inc.
Statement on Form S-3

Re: Rubius

Registration

Filed June 8, 2022
File No. 333-265482

Dear Dr. Cagnoni:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler

Howes at 202-551-3370 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Yasin Akbari, Esq.